Monomeric Targeted Protein Degraders

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII of original article: S0169-409X(96)00423-1. The article was originally published in Advanced Drug Delivery Reviews 23 (1997) 3–25. 1

Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139 · see citing works

The phosphatidylinositol 3-Kinase–AKT pathway in human cancer

Vivanco, I., & Sawyers, C. L. (2002) · Nature reviews. Cancer · doi:10.1038/nrc839 · Cited by 6,041 · see citing works

The phosphoinositide 3-kinase pathway

Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621 · see citing works

The Epigenomics of Cancer

Jones, P. A., & Baylin, S. B. (2007) · Cell · doi:10.1016/j.cell.2007.01.029 · Cited by 4,515 · see citing works

Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing

Cao, R., Wang, L., Wang, H., Xia, L., Erdjument-Bromage, H., Tempst, P., Jones, R. S., & Zhang, Y. (2002) · Science · doi:10.1126/science.1076997 · Cited by 3,775 · see citing works

High Frequency of Mutations of the PIK3CA Gene in Human Cancers

Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A. F., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,448 · see citing works

Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and Its Application to the Prediction of Drug Transport Properties

Ertl, P., Rohde, B., & Selzer, P. M. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000942e · Cited by 3,149 · see citing works

Targeting the phosphoinositide 3-kinase pathway in cancer

Liu, P., Cheng, H.-L. M., Roberts, T. M., & Zhao, J. J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2926 · Cited by 2,722 · see citing works

The polycomb group protein EZH2 is involved in progression of prostate cancer

Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., Ghosh, D., Pienta, K. J., Sewalt, R. G. A. B., Otte, A. P., et al. (2002) · Nature · doi:10.1038/nature01075 · Cited by 2,717 · see citing works

Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules.

Rock, K. L., Gramm, C., Rothstein, L., Clark, K., Stein, R., Dick, L., Hwang, D., & Goldberg, A. L. (1994) · Cell · doi:10.1016/s0092-8674(94)90462-6 · Cited by 2,524 · see citing works

Thalidomide is an inhibitor of angiogenesis.

D'Amato, R. J., Loughnan, M. S., Flynn, E., & Folkman, J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.4082 · Cited by 2,454 · see citing works

Amplification of N- myc in Untreated Human Neuroblastomas Correlates with Advanced Disease Stage

Brodeur, G. M., Seeger, R. C., Schwab, M., VARMUS, H. E., & Bishop, J. M. (1984) · Science · doi:10.1126/science.6719137 · Cited by 2,261 · see citing works

Identification of a Primary Target of Thalidomide Teratogenicity

Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H. (2010) · Science · doi:10.1126/science.1177319 · Cited by 2,136 · see citing works

An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer

Soucy, T. A., Smith, P. G., Milhollen, M. A., Berger, A. J., Gavin, J. M., Adhikari, S., Brownell, J. E., Burke, K. E., Cardin, D. P., Critchley, S., et al. (2009) · Nature · doi:10.1038/nature07884 · Cited by 1,990 · see citing works

Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells

Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., et al. (2014) · Science · doi:10.1126/science.1244851 · Cited by 1,879 · see citing works

EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations

McCabe, M. T., Ott, H. M., Ganji, G., Korenchuk, S., Thompson, C., Van Aller, G. S., Liu, Y., Graves, A. P., III, A. D. P., Diaz, E., et al. (2012) · Nature · doi:10.1038/nature11606 · Cited by 1,786 · see citing works

IAP proteins: blocking the road to death's door

Salvesen, G. S., & Duckett, C. S. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm830 · Cited by 1,756 · see citing works

PI3K and cancer: lessons, challenges and opportunities

Fruman, D. A., & Rommel, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4204 · Cited by 1,716 · see citing works

EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells

Kleer, C. G., Cao, Q., Varambally, S., Shen, R., Ota, I., Tomlins, S. A., Ghosh, D., Sewalt, R. G. A. B., Otte, A. P., Hayes, D. F., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1933744100 · Cited by 1,649 · see citing works

Engineered Luciferase Reporter from a Deep Sea Shrimp Utilizing a Novel Imidazopyrazinone Substrate

Hall, M. P., Unch, J., Binkowski, B. F., Valley, M. P., Butler, B. L., Wood, M. G., Otto, P., Zimmerman, K., Vidugiris, G. J. A., Machleidt, T., et al. (2012) · ACS Chemical Biology · doi:10.1021/cb3002478 · Cited by 1,588 · see citing works

The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins

Lu, G., Middleton, R. E., Sun, H., Naniong, M., Ott, C. J., Mitsiades, C. S., Wong, K.-K., Bradner, J. E., & Kaelin, W. G. (2014) · Science · doi:10.1126/science.1244917 · Cited by 1,583 · see citing works

The HSP90 chaperone machinery

Schopf, F. H., Biebl, M. M., & Buchner, J. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.20 · Cited by 1,540 · see citing works

The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention

O'Shea, J., Schwartz, D., Villarino, A. V., Gadina, M., Mcinnes, I., & Laurence, A. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-051113-024537 · Cited by 1,472 · see citing works

Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation.

Whitesell, L., Mimnaugh, E. G., De Costa, B., Myers, C. E., & Neckers, L. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.18.8324 · Cited by 1,444 · see citing works

The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine

Tu, Y. (2011) · Nature Medicine · doi:10.1038/nm.2471 · Cited by 1,397 · see citing works

Polycomb silencers control cell fate, development and cancer

Sparmann, A., & van Lohuizen, M. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1991 · Cited by 1,294 · see citing works

ESR1 ligand-binding domain mutations in hormone-resistant breast cancer

Toy, W., Shen, Y., Won, H. H., Green, B., Sakr, R. A., Will, M., Li, Z., Gala, K. P., Fanning, S. W., King, T. A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2822 · Cited by 1,252 · see citing works

Mechanisms and consequences of Jak–STAT signaling in the immune system

Villarino, A. V., Kanno, Y., & O'Shea, J. J. (2017) · Nature Immunology · doi:10.1038/ni.3691 · Cited by 1,221 · see citing works

IAP Antagonists Induce Autoubiquitination of c-IAPs, NF-κB Activation, and TNFα-Dependent Apoptosis

Varfolomeev, E., Blankenship, J. W., Wayson, S. M., Fedorova, A. V., Kayagaki, N., Garg, P., Zobel, K., Dynek, J. N., Elliott, L. O., Wallweber, H. J. A., et al. (2007) · Cell · doi:10.1016/j.cell.2007.10.030 · Cited by 1,218 · see citing works

Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes.

Sampaio, E. P., Sarno, E. N., Gallily, R., Cohn, Z. A., & Kaplan, G. (1991) · The Journal of Experimental Medicine · doi:10.1084/jem.173.3.699 · Cited by 1,191 · see citing works

A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling

Knight, Z. A., Gonzalez, B., Feldman, M. E., Zunder, E. R., Goldenberg, D. D., Williams, O., Loewith, R., Stokoe, D., Balla, A., Toth, B., et al. (2006) · Cell · doi:10.1016/j.cell.2006.03.035 · Cited by 1,174 · see citing works

Activating ESR1 mutations in hormone-resistant metastatic breast cancer

Robinson, D. R., Wu, Y.-M., Vats, P., Su, F., Lonigro, R. J., Cao, X., Kalyana-Sundaram, S., Wang, R., Ning, Y., Hodges, L., et al. (2013) · Nature Genetics · doi:10.1038/ng.2823 · Cited by 1,145 · see citing works

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies

Advani, R. H., Buggy, J. J., Sharman, J. P., Smith, S. M., Boyd, T. E., Grant, B., Kolibaba, K. S., Furman, R. R., Rodriguez, S., Chang, B. Y., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.7906 · Cited by 1,128 · see citing works

Untitled work

(1991) · PubMed · Cited by 1,101 · see citing works

IAP Antagonists Target cIAP1 to Induce TNFα-Dependent Apoptosis

Vince, J. E., Wong, W. W.-L., Khan, N. R., Feltham, R., Chau, D., Ahmed, A. U., Benetatos, C. A., Chunduru, S. K., Condon, S. M., McKinlay, M. A., et al. (2007) · Cell · doi:10.1016/j.cell.2007.10.037 · Cited by 1,061 · see citing works

An integrative genomic and proteomic analysis of pik3ca, pten, and akt mutations in breast cancer.

Stemke-Hale, K., Gonzalez-Angulo, A. M., Lluch, A., Neve, R. M., Kuo, W.-L., Davies, M., Carey, M., Hu, Z., Guan, Y., Sahin, A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6854 · Cited by 1,054 · see citing works

Inhibition of eukaryotic translation elongation by cycloheximide and lactimidomycin

Schneider‐Poetsch, T., Ju, J., Eyler, D. E., Dang, Y., Bhat, S., Merrick, W. C., Green, R., Shen, B., & Liu, J. O. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.304 · Cited by 1,020 · see citing works

Extraction of Cholesterol with Methyl-β-Cyclodextrin Perturbs Formation of Clathrin-coated Endocytic Vesicles

Rodal, S. K., Skretting, G., Garred, Ø., Vilhardt, F., van Deurs, B., & Sandvig, K. (1999) · Molecular Biology of the Cell · doi:10.1091/mbc.10.4.961 · Cited by 1,009 · see citing works

Flow cytometry: basic principles and applications

Adan, A., Alizada, G., Kiraz, Y., Baran, Y., & Nalbant, A. (2016) · Critical Reviews in Biotechnology · doi:10.3109/07388551.2015.1128876 · Cited by 925 · see citing works

Mutant PIK3CA promotes cell growth and invasion of human cancer cells.

Samuels, Y., Diaz, L. A., Schmidt-Kittler, O., Cummins, J. M., DeLong, L., Cheong, I., Rago, C., Huso, D. L., Lengauer, C., Kinzler, K. W., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.05.014 · Cited by 915 · see citing works

EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent

Xu, K., Wu, Z. J., Groner, A. C., He, H. H., Cai, C., Lis, R. T., Wu, X., Stack, E. C., Loda, M. F., Liu, T., et al. (2012) · Science · doi:10.1126/science.1227604 · Cited by 877 · see citing works

PIK3CA Mutations Correlate with Hormone Receptors, Node Metastasis, and ERBB2, and Are Mutually Exclusive with PTEN Loss in Human Breast Carcinoma

Saal, L. H., Holm, K., Maurer, M. S., Memeo, L., Su, T., Wang, X., Yu, J. S., Malmström, P.-O., MANSUKHANI, M. M., Enoksson, J., et al. (2005) · Cancer Research · doi:10.1158/0008-5472-can-04-3913 · Cited by 877 · see citing works

Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS

Krönke, J., Fink, E. C., Hollenbach, P. W., MacBeth, K. J., Hurst, S. N., Udeshi, N. D., Chamberlain, P. P., Mani, D. R., Man, H. W., Gandhi, A. K., et al. (2015) · Nature · doi:10.1038/nature14610 · Cited by 863 · see citing works

PROteolysis TArgeting Chimeras (PROTACs) — Past, present and future

Pettersson, M., & Crews, C. M. (2019) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2019.01.002 · Cited by 818 · see citing works

Structural Insights into NEDD8 Activation of Cullin-RING Ligases: Conformational Control of Conjugation

Duda, D. M., Borg, L. A., Scott, D. C., Hunt, H. W., Hammel, M., & Schulman, B. A. (2008) · Cell · doi:10.1016/j.cell.2008.07.022 · Cited by 767 · see citing works

Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15

Han, T., Goralski, M., Gaskill, N., Capota, E., Kim, J., Ting, T. C., Xie, Y., Williams, N. S., & Nijhawan, D. (2017) · Science · doi:10.1126/science.aal3755 · Cited by 762 · see citing works

Human Caspases: Activation, Specificity, and Regulation

Pop, C., & Salvesen, G. S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.r800084200 · Cited by 757 · see citing works

A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase

Matyskiela, M. E., Lu, G., Ito, T., Pagarigan, B., Lu, C.-C., Miller, K., Fang, W., Wang, N.-Y., Nguyen, D., Houston, J., et al. (2016) · Nature · doi:10.1038/nature18611 · Cited by 701 · see citing works

Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome

Demo, S. D., Kirk, C. J., Aujay, M. A., Buchholz, T. J., Dajee, M., Ho, M. N., Jiang, J., Laidig, G. J., Lewis, E. R., Parlati, F., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4086 · Cited by 681 · see citing works

Monitoring lymphocyte proliferation in vitro and in vivo with the intracellular fluorescent dye carboxyfluorescein diacetate succinimidyl ester

Quah, B., Warren, H. S., & Parish, C. R. (2007) · Nature Protocols · doi:10.1038/nprot.2007.296 · Cited by 628 · see citing works

A short history, principles, and types of ELISA, and our laboratory experience with peptide/protein analyses using ELISA.

Aydin, S. (2015) · Peptides · doi:10.1016/j.peptides.2015.04.012 · Cited by 626 · see citing works

Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts

Li, S., Shen, D., Shao, J., Crowder, R. J., Liu, W., Prat, A., He, X., Liu, S., Hoog, J., Lu, C., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.08.022 · Cited by 623 · see citing works

Structural basis of lenalidomide-induced CK1α degradation by the CRL4CRBN ubiquitin ligase

Petzold, G., Fischer, E. S., & Thomä, N. H. (2016) · Nature · doi:10.1038/nature16979 · Cited by 620 · see citing works

Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation

Kondo, Y., Shen, L., Cheng, A. S. L., Ahmed, S., Boumber, Y., Charo, C., Yamochi, T., Urano, T., Furukawa, K., Kwabi‐Addo, B., et al. (2008) · Nature Genetics · doi:10.1038/ng.159 · Cited by 618 · see citing works

Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases

Clark, J. D., Flanagan, M. E., & Telliez, J. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401490p · Cited by 615 · see citing works

IAPs, RINGs and ubiquitylation

Vaux, D. L., & Silke, J. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1621 · Cited by 611 · see citing works

Ezh2 Orchestrates Gene Expression for the Stepwise Differentiation of Tissue-Specific Stem Cells

Ezhkova, E., Pasolli, H. A., Parker, J. S., Stokes, N., Su, I.-H., Hannon, G. J., Tarakhovsky, A., & Fuchs, E. V. (2009) · Cell · doi:10.1016/j.cell.2008.12.043 · Cited by 599 · see citing works

Targeted protein degradation by PROTACs

Neklesa, T. K., Winkler, J. D., & Crews, C. M. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.027 · Cited by 599 · see citing works

Isobaric Labeling-Based Relative Quantification in Shotgun Proteomics

Rauniyar, N., & Yates, J. R. (2014) · Journal of Proteome Research · doi:10.1021/pr500880b · Cited by 597 · see citing works

Acute cholesterol depletion inhibits clathrin-coated pit budding

Subtil, A., Gaidarov, I., Kobylarz, K. A., Lampson, M. A., Keen, J. H., & McGraw, T. E. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.12.6775 · Cited by 577 · see citing works

Stabilization of N-Myc Is a Critical Function of Aurora A in Human Neuroblastoma

Otto, T., Horn, S., Brockmann, M., Eilers, U., Schüttrumpf, L., Popov, N., Kenney, A. M., Schulte, J. H., Beijersbergen, R. L., Christiansen, H., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.12.005 · Cited by 574 · see citing works

Thalidomide Costimulates Primary Human T Lymphocytes, Preferentially Inducing Proliferation, Cytokine Production, and Cytotoxic Responses in the CD8+ Subset

Haslett, P. A. J., Corral, L. G., Albert, M. L., & Kaplan, G. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.11.1885 · Cited by 572 · see citing works

The inhibitors of apoptosis (IAPs) as cancer targets

Hunter, A. M., LaCasse, E. C., & Korneluk, R. G. (2007) · Apoptosis · doi:10.1007/s10495-007-0087-3 · Cited by 565 · see citing works

Polycomb group proteins: navigators of lineage pathways led astray in cancer

Bracken, A. P., & Helin, K. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2736 · Cited by 562 · see citing works

Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs

Chamberlain, P. P., Lopez-Girona, A., Miller, K., Carmel, G., Pagarigan, B., Chie-Leon, B., Rychak, E., Corral, L. G., Ren, Y. J., Wang, M., et al. (2014) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2874 · Cited by 531 · see citing works

Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2 -Mutant Non-Hodgkin Lymphoma

Knutson, S. K., Kawano, S., Minoshima, Y., Warholic, N. M., Huang, K., Xiao, Y., Kadowaki, T., Uesugi, M., Kuznetsov, G., Kumar, N., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0773 · Cited by 529 · see citing works

Beyond chemotherapy: targeted therapies in ovarian cancer

Yap, T. A., Carden, C. P., & Kaye, S. B. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2583 · Cited by 495 · see citing works

Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?

Churcher, I. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01272 · Cited by 491 · see citing works

Development of targeted protein degradation therapeutics

Chamberlain, P. P., & Hamann, L. G. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0362-y · Cited by 489 · see citing works

The proteasome inhibitor PS-341 in cancer therapy.

Teicher, B. A., Ara, G., Herbst, R. S., Palombella, V. J., & Adams, J. (1999) · PubMed · Cited by 472 · see citing works

Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis

Meyer, D. M., Jesson, M. I., Li, X., Elrick, M. M., Funckes-Shippy, C. L., Warner, J. D., Gross, C. J., Dowty, M. E., Ramaiah, S. K., Hirsch, J. L., et al. (2010) · Journal of Inflammation · doi:10.1186/1476-9255-7-41 · Cited by 464 · see citing works

Critical role for the p110α phosphoinositide-3-OH kinase in growth and metabolic regulation

Foukas, L. C., Claret, M., Pearce, W., Okkenhaug, K., Meek, S., Peskett, E., Sancho, S., Smith, A. J. H., Withers, D. J., & Vanhaesebroeck, B. (2006) · Nature · doi:10.1038/nature04694 · Cited by 463 · see citing works

A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment

Hyer, M. L., Milhollen, M. A., Ciavarri, J., Fleming, P., Traore, T., Sappal, D., Huck, J., Shi, J., Gavin, J., Brownell, J., et al. (2018) · Nature Medicine · doi:10.1038/nm.4474 · Cited by 447 · see citing works

CRISPR-Mediated Tagging of Endogenous Proteins with a Luminescent Peptide

Schwinn, M. K., Machleidt, T., Zimmerman, K., Eggers, C. T., Dixon, A. S., Hurst, R., Hall, M. P., Encell, L. P., Binkowski, B. F., & Wood, K. V. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.7b00549 · Cited by 434 · see citing works

Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2

Deng, X., Dzamko, N. L., Prescott, A. R., Davies, P., Liu, Q., Yang, Q., Lee, J., Patricelli, M. P., Nomanbhoy, T. K., Alessi, D. R., et al. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.538 · Cited by 424 · see citing works

Proteolysis targeting chimeras (PROTACs) in ‘beyond rule-of-five’ chemical space: Recent progress and future challenges

Edmondson, S. D., Yang, B., & Fallan, C. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.04.030 · Cited by 422 · see citing works

Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase

Manfredi, M. G., Ecsedy, J., Meetze, K. A., Balani, S. K., Burenkova, O. V., Chen, W., Galvin, K. M., Hoar, K. M., Huck, J. J., Leroy, P. J., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608798104 · Cited by 412 · see citing works

SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2

Kim, K. H., Kim, W., Howard, T. P., Vázquez, F., Tsherniak, A., Wu, J. N., Wang, W., Haswell, J. R., Walensky, L. D., Hahn, W. C., et al. (2015) · Nature Medicine · doi:10.1038/nm.3968 · Cited by 407 · see citing works

D538G Mutation in Estrogen Receptor-α: A Novel Mechanism for Acquired Endocrine Resistance in Breast Cancer

Merenbakh-Lamin, K., Ben-Baruch, N. E., Yeheskel, A., Dvir, A., Soussan‐Gutman, L., Jeselsohn, R. M., Yelensky, R., Brown, M. A., Miller, V. A., Sarid, D. L., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1197 · Cited by 397 · see citing works

Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser910/Ser935, disruption of 14-3-3 binding and altered cytoplasmic localization

Dzamko, N. L., Deák, M., Hentati, F., Reith, A. D., Prescott, A. R., Alessi, D. R., & Nichols, R. J. (2010) · Biochemical Journal · doi:10.1042/bj20100784 · Cited by 379 · see citing works

LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice

Herzig, M. C., Kolly, C., Persohn, E., Theil, D. J., Schweizer, T., Hafner, T., Stemmelen, C., Troxler, T. J., Schmid, P., Danner, S., et al. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr348 · Cited by 360 · see citing works

Effect of selective LRRK2 kinase inhibition on nonhuman primate lung

Fuji, R. N., Flagella, M., Baca, M., Baptista, M. A. S., Brodbeck, J., Chan, B. K., Fiske, B. K., Honigberg, L. A., Jubb, A. M., Katavolos, P., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa3634 · Cited by 357 · see citing works

Amino-substituted thalidomide analogs: Potent inhibitors of TNF-α production

Muller, G. W., Chen, R., Huang, S., Corral, L. G., Wong, L. M., Patterson, R. T., Chen, Y., Kaplan, G., & Stirling, D. (1999) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(99)00250-4 · Cited by 341 · see citing works

Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection.

Flanagan, M., Blumenkopf, T., Brissette, W., Brown, M. F., Casavant, J. M., Chang, S.-P., Doty, J. L., Elliott, E., Fisher, M., Hines, M., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm1004286 · Cited by 334 · see citing works

Discovery of Novel Antitumor Sulfonamides Targeting G1 Phase of the Cell Cycle

Owa, T., Yoshino, H., Okauchi, T., Yoshimatsu, K., Ozawa, Y., Sugi, N. H., Nagasu, T., Koyanagi, N., & Kitoh, K. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm9902638 · Cited by 322 · see citing works

MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition

Fell, M. J., Mirescu, C., Basu, K., Cheewatrakoolpong, B., DeMong, D. E., Ellis, J. M., Hyde, L. A., Lin, Y., Markgraf, C. G., Mei, H., et al. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.227587 · Cited by 310 · see citing works

A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos

Matyskiela, M. E., Zhang, W., Man, H.-W., Muller, G., Khambatta, G., Baculi, F., Hickman, M., LeBrun, L., Pagarigan, B., Carmel, G., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01921 · Cited by 309 · see citing works

Quantitative Live-Cell Kinetic Degradation and Mechanistic Profiling of PROTAC Mode of Action

Riching, K. M., Mahan, S. D., Corona, C. R., McDougall, M. G., Vasta, J. D., Robers, M. B., Urh, M., & Daniels, D. L. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.8b00692 · Cited by 307 · see citing works

Small Molecule Inhibitors of Aurora-A Induce Proteasomal Degradation of N-Myc in Childhood Neuroblastoma

Brockmann, M., Poon, E., Berry, T., Carstensen, A., Deubzer, H. E., Rycak, L., Jamin, Y., Thway, K., Robinson, S. P., Roels, F., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.05.005 · Cited by 300 · see citing works

Inhibition of Myc family proteins eradicates KRas-driven lung cancer in micePreprint

Soucek, L., Whitfield, J. R., Sodir, N. M., Massó-Vallés, D., Serrano, E., Karnezis, A. N., Swigart, L. B., & Evan, G. I. (2013) · Genes & Development · doi:10.1101/gad.205542.112 · Cited by 299 · see citing works

Drugging MYCN through an Allosteric Transition in Aurora Kinase A

Gustafson, W. C., Meyerowitz, J., Nekritz, E. A., Chen, J., Benes, C. H., Charron, E., Simonds, E. F., Seeger, R. C., Matthay, K. K., Hertz, N. T., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.07.015 · Cited by 280 · see citing works

A Potent and Orally Active Antagonist (SM-406/AT-406) of Multiple Inhibitor of Apoptosis Proteins (IAPs) in Clinical Development for Cancer Treatment

Cai, Q., Sun, H., Peng, Y., Lü, J., Nikolovska‐Coleska, Z., McEachern, D., Liu, L., Qiu, S., Yang, C., Miller, R. S., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101505d · Cited by 274 · see citing works

The Use of AlphaScreen Technology in HTS: Current Status

Eglen, R. M., Reisine, T., Roby, P., Rouleau, N., Illy, C., Bossé, R., & Bielefeld, M. (2008) · Current Chemical Genomics · doi:10.2174/1875397300801010002 · Cited by 261 · see citing works

Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts

Lai, A. G., Kahraman, M., Govek, S. P., Nagasawa, J. Y., Bonnefous, C., Julien, J., Douglas, K. L., Sensintaffar, J., Lu, N., Lee, K., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00054 · Cited by 253 · see citing works

Discovery of a Potent Small-Molecule Antagonist of Inhibitor of Apoptosis (IAP) Proteins and Clinical Candidate for the Treatment of Cancer (GDC-0152)

Flygare, J. A., Beresini, M., Budha, N., Chan, H., Chan, I. T., Cheeti, S., Cohen, F., Deshayes, K., Doerner, K., Eckhardt, S. G., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300060k · Cited by 252 · see citing works

Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells

Babaei, M. A., Kamalıdehghan, B., Saleem, M., et al. (2016) · Drug Design Development and Therapy · doi:10.2147/dddt.s89114 · Cited by 252 · see citing works

Development of artemisinin compounds for cancer treatment

Lai, H. C., Singh, N. P., & Sasaki, T. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9873-z · Cited by 235 · see citing works

Antagonists Induce a Conformational Change in cIAP1 That Promotes Autoubiquitination

Dueber, E. C., Schoeffler, A. J., Lingel, A., Elliott, J. M., Fedorova, A. V., Giannetti, A. M., Zobel, K., Maurer, B., Varfolomeev, E. E., Wu, P., et al. (2011) · Science · doi:10.1126/science.1207862 · Cited by 232 · see citing works

Measuring Residual Estrogen Receptor Availability during Fulvestrant Therapy in Patients with Metastatic Breast Cancer

van Kruchten, M., de Vries, E. G. E., Glaudemans, A. W. J. M., van Lanschot, M. C. J., van Faassen, M., Kema, I. P., Brown, M., Schröder, C. P., de Vries, E. F., & Hospers, G. A. P. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0697 · Cited by 229 · see citing works

Identification of ( R )- N -((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1 H -indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymphomas

Vaswani, R. G., Gehling, V. S., Dakin, L. A., Cook, A. S., Nasveschuk, C. G., Duplessis, M., Iyer, P., Balasubramanian, S., Zhao, F., Good, A. C., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01315 · Cited by 226 · see citing works

Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility

Guan, J., Zhou, W. J., Hafner, M. A., Blake, R. A., Chalouni, C. M., Chen, I. P., Bruyn, T. D., Giltnane, J. M., Hartman, S. J., Heidersbach, A. J., et al. (2019) · Cell · doi:10.1016/j.cell.2019.06.026 · Cited by 216 · see citing works

Chemically Induced Degradation of the Oncogenic Transcription Factor BCL6

Kerres, N., Steurer, S., Schlager, S., Bader, G., Berger, H., Caligiuri, M., Dank, C., Engen, J. R., Ettmayer, P., Fischerauer, B., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.08.081 · Cited by 207 · see citing works

CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL

Hagner, P. R., Man, H.-W., Fontanillo, C., Wang, M., Couto, S., Breider, M., Bjorklund, C., Havens, C. G., Lu, G., Rychak, E., et al. (2015) · Blood · doi:10.1182/blood-2015-02-628669 · Cited by 203 · see citing works

Myc proteins as therapeutic targets

Gustafson, W. C., & Weiss, W. A. (2010) · Oncogene · doi:10.1038/onc.2009.512 · Cited by 199 · see citing works

PROTAC-Mediated Degradation of Bruton’s Tyrosine Kinase Is Inhibited by Covalent Binding

Tinworth, C. P., Lithgow, H., Dittus, L., Bassi, Z. I., Hughes, S. E., Muelbaier, M., Dai, H., Smith, I. E. D., Kerr, W. J., Burley, G. A., et al. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.8b01094 · Cited by 195 · see citing works

Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker

Takawa, M., Masuda, K., Kunizaki, M., Daigo, Y., Takagi, K., Iwai, Y., Cho, H., Toyokawa, G., Yamane, Y., Maejima, K., et al. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.01958.x · Cited by 192 · see citing works

The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: A structural analysis of the binding interactions of Gleevec®, Nexavar®, and BIRB-796

Dietrich, J. D., Hulme, C., & Hurley, L. H. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.05.063 · Cited by 188 · see citing works

Molecular chaperones and protein kinase quality control

Caplan, A. J., Mandal, A. K., & Theodoraki, M. A. (2006) · Trends in Cell Biology · doi:10.1016/j.tcb.2006.12.002 · Cited by 185 · see citing works

Discovery of 2-{3-[2-(1-Isopropyl-3-methyl-1H-1,2–4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): A β-Sparing Phosphoinositide 3-Kinase Inhibitor with High Unbound Exposure and Robust in Vivo Antitumor Activity

Ndubaku, C. O., Heffron, T. P., Staben, S. T., Baumgardner, M., Blaquière, N., Bradley, E. K., Bull, R., Do, S., Dotson, J., Dudley, D. A., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4003632 · Cited by 182 · see citing works

Dihydroartemisinin induces apoptosis and sensitizes human ovarian cancer cells to carboplatin therapy

Chen, T., Li, M., Zhang, R., & Wang, H. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00360.x · Cited by 181 · see citing works

Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplification

Kim, Y. H., Girard, L., Giacomini, C. P., Wang, P., Hernandez‐Boussard, T., Tibshirani, R. J., Minna, J. D., & Pollack, J. R. (2005) · Oncogene · doi:10.1038/sj.onc.1208997 · Cited by 181 · see citing works

Structural Basis and Kinetic Pathway of RBM39 Recruitment to DCAF15 by a Sulfonamide Molecular Glue E7820

Du, X., Volkov, O. A., Czerwinski, R. M., Tan, H., Huerta, C., Morton, E. R., Rizzi, J. P., Wehn, P. M., Xu, R., Nijhawan, D., et al. (2019) · Structure · doi:10.1016/j.str.2019.10.005 · Cited by 181 · see citing works

Loss of Leucine-Rich Repeat Kinase 2 (LRRK2) in Rats Leads to Progressive Abnormal Phenotypes in Peripheral Organs

Baptista, M. A. S., Dave, K. D., Frasier, M. A., Sherer, T., Greeley, M. A., Beck, M. J., Varsho, J. S., Parker, G. A., Moore, C., Churchill, M. J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080705 · Cited by 178 · see citing works

Oral Selective Estrogen Receptor Downregulators (SERDs), a Breakthrough Endocrine Therapy for Breast Cancer

McDonnell, D. P., Wardell, S. E., & Norris, J. D. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00760 · Cited by 178 · see citing works

The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review

Liang, C., Tian, D., Ren, X., Ding, S., Jia, M., Xin, M., & Thareja, S. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.03.062 · Cited by 178 · see citing works

Optimization of a Novel Binding Motif to ( E )-3-(3,5-Difluoro-4-((1 R ,3 R )-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1 H -pyrido[3,4- b ]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist

Savi, C. D., Bradbury, R. H., Rabow, A. A., Norman, R. A., de Almeida, C., Andrews, D. M., Ballard, P. G., Buttar, D., Callis, R. J., Currie, G. S., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00984 · Cited by 169 · see citing works

Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy

Ihle, N. T., & Powis, G. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0801 · Cited by 166 · see citing works

EZH2 overexpression in natural killer/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity

Yan, J., Ng, S., Tay, J. L.-S., Lin, B., Koh, T. L., Tan, J. M.-L., Selvarajan, V., Liu, S.-C., Bi, C., Wang, S., et al. (2013) · Blood · doi:10.1182/blood-2012-08-450494 · Cited by 165 · see citing works

Detection of Intracellular Cytokines by Flow Cytometry

Yin, Y., Mitson‐Salazar, A., & Prussin, C. (2015) · Current Protocols in Immunology · doi:10.1002/0471142735.im0624s110 · Cited by 162 · see citing works

Therapeutic Targeting of Myc

Prochownik, E. V., & Vogt, P. K. (2010) · Genes & Cancer · doi:10.1177/1947601910377494 · Cited by 150 · see citing works

U.S. Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients with Intermediate and High-Risk Myelofibrosis

Deisseroth, A., Kaminskas, E., Grillo, J. A., Chen, W., Saber, H., Lu, H., Rothmann, M. D., Brar, S. S., Wang, J., Garnett, C. E., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0653 · Cited by 149 · see citing works

The N-myc Oncogene: Maximizing its Targets, Regulation, and Therapeutic Potential

Beltran, H. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0536 · Cited by 148 · see citing works

The Cdk1 Complex Plays a Prime Role in Regulating N-Myc Phosphorylation and Turnover in Neural Precursors

Sjostrom, S. K., Finn, G., Hahn, W. C., Rowitch, D. H., & Kenney, A. M. (2005) · Developmental Cell · doi:10.1016/j.devcel.2005.07.014 · Cited by 147 · see citing works

Dihydroartemisinin is an inhibitor of ovarian cancer cell growth

Jiao, Y., Ge, C., Meng, Q., Cao, J., Tong, J., & Fan, S. (2007) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2007.00612.x · Cited by 146 · see citing works

BTK Signaling in B Cell Differentiation and Autoimmunity

Corneth, O. B. J., Wolterink, R. G. J. K., & Hendriks, R. W. (2015) · Current topics in microbiology and immunology · doi:10.1007/82_2015_478 · Cited by 140 · see citing works

ATP-competitive inhibitors block protein kinase recruitment to the Hsp90-Cdc37 system

Polier, S., Samant, R. S., Clarke, P. A., Workman, P., Prodromou, C., & Pearl, L. H. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1212 · Cited by 140 · see citing works

Phosphopeptide Analysis Reveals Two Discrete Clusters of Phosphorylation in the N-Terminus and the Roc Domain of the Parkinson-Disease Associated Protein Kinase LRRK2

Gloeckner, C. J., Boldt, K., von Zweydorf, F., Helm, S., Wiesent, L., Sarioglu, H., & Ueffing, M. (2010) · Journal of Proteome Research · doi:10.1021/pr9008578 · Cited by 139 · see citing works

Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC To Provide Insight into Small Molecule Targeting of BCL6

McCoull, W., Cheung, T., Anderson, E., Barton, P., Burgess, J., Byth, K., Cao, Q., Castaldi, M. P., Chen, H., Chiarparin, E., et al. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.8b00698 · Cited by 139 · see citing works

Mutant LRRK2 Toxicity in Neurons Depends on LRRK2 Levels and Synuclein But Not Kinase Activity or Inclusion Bodies

Skibinski, G., Nakamura, K., Cookson, M., & Finkbeiner, S. M. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.2712-13.2014 · Cited by 138 · see citing works

Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate ( R )-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2 H )-one (PF-06821497)

Kung, P., Bingham, P., Brooun, A., Collins, M. R., Deng, Y., Dinh, D. M., Fan, C., Gajiwala, K. S., Grantner, R., Gukasyan, H. J., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01375 · Cited by 138 · see citing works

Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA -mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER.

Baselga, J. M., Dent, S. F., Cortés, J., Im, Y., Dieras, V. C., Harbeck, N., Krop, I. E., Verma, S., Wilson, T. R., Jin, H., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.18_suppl.lba1006 · Cited by 138 · see citing works

Enzyme‐Linked Immunosorbent Assays

Hornbeck, P. V. (2015) · Current Protocols in Immunology · doi:10.1002/0471142735.im0201s110 · Cited by 137 · see citing works

Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer

Tria, G. S., Abrams, T. J., Baird, J., Burks, H. E., Firestone, B., Gaither, L. A., Hamann, L. G., He, G., Kirby, C. A., Kim, S., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01682 · Cited by 134 · see citing works

Protein Detection by Simple Western™ Analysis

Harris, V. M. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2694-7_47 · Cited by 125 · see citing works

Lys05

Amaravadi, R. K., & Winkler, J. D. (2012) · Autophagy · doi:10.4161/auto.20958 · Cited by 123 · see citing works

The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer

Joseph, J. D., Darimont, B. D., Zhou, W. J., Arrazate, A., Young, A. E., Ingalla, E., Walter, K., Blake, R. A., Nonomiya, J., Guan, Z., et al. (2016) · eLife · doi:10.7554/elife.15828 · Cited by 122 · see citing works

Drug-Resistant Aurora A Mutants for Cellular Target Validation of the Small Molecule Kinase Inhibitors MLN8054 and MLN8237

Sloane, D. A., Trikić, M. Z., Chu, M. L.-H., et al. (2010) · ACS Chemical Biology · doi:10.1021/cb100053q · Cited by 119 · see citing works

Inhibitor of Apoptosis Protein (IAP) Antagonists in Anticancer Agent Discovery: Current Status and Perspectives

Cong, H., Xu, L., Wu, Y., Qu, Z., Bian, T., Zhang, W., Xing, C., & Zhuang, C. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01668 · Cited by 113 · see citing works

Protein degradation through covalent inhibitor-based PROTACs

Xue, G., Chen, J., Liu, L., Zhou, D., Zuo, Y., Fu, T., & Pan, Z. (2020) · Chemical Communications · doi:10.1039/c9cc08238g · Cited by 109 · see citing works

Degradation of short and long lived proteins in isolated rat liver lysosomes. Effects of pH, temperature, and proteolytic inhibitors.

Ahlberg, J., Berkenstam, A. L., Henell, F., & Glaumann, H. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)89099-8 · Cited by 107 · see citing works

Systematic Structure Modifications of Multitarget Prostate Cancer Drug Candidate Galeterone To Produce Novel Androgen Receptor Down-Regulating Agents as an Approach to Treatment of Advanced Prostate Cancer

Purushottamachar, P., Godbole, A. M., Gediya, L. K., Martin, M. S., Vasaitis, T. S., Kwegyir‐Afful, A. K., Ramalingam, S., Ateş‐Alagöz, Z., & Njar, V. C. O. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400048v · Cited by 104 · see citing works

Bifunctional chemical probes inducing protein–protein interactions

Maniaci, C., & Ciulli, A. (2019) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2019.07.003 · Cited by 100 · see citing works

Metabolic Labeling with Noncanonical Amino Acids and Visualization by Chemoselective Fluorescent Tagging

Dieck, S. T., Müller, A., Nehring, A., Hinz, F. I., Bartnik, I., Schuman, E. M., & Dieterich, D. C. (2012) · Current Protocols in Cell Biology · doi:10.1002/0471143030.cb0711s56 · Cited by 99 · see citing works

A covalently bound inhibitor triggers EZH2 degradation through CHIP‐mediated ubiquitination

Wang, X., Cao, W., Zhang, J., Yan, M., Xu, Q., Wu, X., Wan, L., Zhang, Z., Zhang, C., Qin, X., et al. (2017) · The EMBO Journal · doi:10.15252/embj.201694058 · Cited by 99 · see citing works

How Hsp90 and Cdc37 Lubricate Kinase Molecular Switches

Verba, K. A., & Agard, D. A. (2017) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2017.07.002 · Cited by 98 · see citing works

The specificity of JAK3 kinase inhibitors

Changelian, P. S., Moshinsky, D. J., Kuhn, C. F., et al. (2007) · Blood · doi:10.1182/blood-2007-09-115030 · Cited by 95 · see citing works

Neratinib induces ErbB2 ubiquitylation and endocytic degradation via HSP90 dissociation in breast cancer cells

Zhang, Y., Zhang, J., Liu, C., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.08.026 · Cited by 95 · see citing works

Novel Selective Agents for the Degradation of Androgen Receptor Variants to Treat Castration-Resistant Prostate Cancer

Ponnusamy, S., Coss, C. C., Thiyagarajan, T., Watts, K., Hwang, D., He, Y., Selth, L. A., McEwan, I. J., Duke, C. B., Pagadala, J., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0976 · Cited by 95 · see citing works

Crystal structure of an Aurora-A mutant that mimics Aurora-B bound to MLN8054: insights into selectivity and drug design

Dodson, C. A., Kosmopoulou, M. N., Richards, M. W., Atrash, B., Bavetsias, V., Blagg, J., & Bayliss, R. W. (2010) · Biochemical Journal · doi:10.1042/bj20091530 · Cited by 94 · see citing works

C-KIT Signaling in Cancer Treatment

Stankov, K., Popović, S., & Mikov, M. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113199990593 · Cited by 94 · see citing works

Mechanistic Studies of Substrate-assisted Inhibition of Ubiquitin-activating Enzyme by Adenosine Sulfamate Analogues

Chen, J. J., Tsu, C. A., Gavin, J. M., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.279984 · Cited by 93 · see citing works

Discovery of 6-(2,4-Dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid (SAR439859), a Potent and Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen-Receptor-Positive Breast Cancer

El‐Ahmad, Y., Tabart, M., Halley, F., Certal, V., Thompson, F., Filoche-Rommé, B., Gruss-Leleu, F., Muller, C., Brollo, M., Fabien, L., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01293 · Cited by 90 · see citing works

Basic Multicolor Flow Cytometry

Maciorowski, Z., Chattopadhyay, P. K., & Jain, P. (2017) · Current Protocols in Immunology · doi:10.1002/cpim.26 · Cited by 87 · see citing works

Fulvestrant-3 Boronic Acid (ZB716): An Orally Bioavailable Selective Estrogen Receptor Downregulator (SERD)

Liu, J., Zheng, S., Akerstrom, V. L., Yuan, C., Ma, Y., Zhong, Q., Zhang, C., Zhang, Q., Guo, S., Ma, P., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00753 · Cited by 86 · see citing works

Gambogenic acid induces G1 arrest via GSK3β-dependent cyclin D1 degradation and triggers autophagy in lung cancer cells

Yu, X., Han, Q., Wen, Z., Ma, L., Gao, J., & Zhou, G. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.03.004 · Cited by 83 · see citing works

The search for ESR1 mutations in breast cancer

Oesterreich, S., & Davidson, N. E. (2013) · Nature Genetics · doi:10.1038/ng.2831 · Cited by 82 · see citing works

LRRK2 Kinase Inhibition as a Therapeutic Strategy for Parkinson's Disease, Where Do We Stand?

Taymans, J., & Greggio, E. (2016) · Current Neuropharmacology · doi:10.2174/1570159x13666151030102847 · Cited by 81 · see citing works

AZD3514: A Small Molecule That Modulates Androgen Receptor Signaling and Function In Vitro and In Vivo

Loddick, S. A., Ross, S. J., Thomason, A. G., Robinson, D. M., Walker, G. E., Dunkley, T. P. J., Brave, S. R., Broadbent, N., Stratton, N. C., Trueman, D., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1174 · Cited by 79 · see citing works

Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927

Kahraman, M., Govek, S. P., Nagasawa, J. Y., Lai, A. G., Bonnefous, C., Douglas, K. L., Sensintaffar, J., Liu, N., Lee, K., Aparicio, A. M., et al. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00414 · Cited by 78 · see citing works

Discovery of a Potent, Covalent BTK Inhibitor for B-Cell Lymphoma

Wu, H., Wang, W., Liu, F., Weisberg, E., Tian, B., Chen, Y., Li, B., Wang, A., Wang, B., Zhao, Z., et al. (2014) · ACS Chemical Biology · doi:10.1021/cb4008524 · Cited by 76 · see citing works

Evidence That a Rapidly Turning Over Protein, Normally Degraded by Proteasomes, Regulates hsp72 Gene Transcription in HepG2 Cells

Zhou, M., Wu, X., & Ginsberg, H. N. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.40.24769 · Cited by 75 · see citing works

Pharmacological LRRK2 kinase inhibition induces LRRK2 protein destabilization and proteasomal degradation

Lobbestael, E., Civiero, L., Wit, T. D., Taymans, J., Greggio, E., & Baekelandt, V. (2016) · Scientific Reports · doi:10.1038/srep33897 · Cited by 73 · see citing works

New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity

Hwang, D., He, Y., Ponnusamy, S., Mohler, M. L., Thiyagarajan, T., McEwan, I. J., Narayanan, R., & Miller, D. D. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00973 · Cited by 73 · see citing works

LRRK2 dephosphorylation increases its ubiquitination

Zhao, J., Molitor, T. P., Langston, J. W., & Nichols, R. J. (2015) · Biochemical Journal · doi:10.1042/bj20141305 · Cited by 69 · see citing works

Small-Molecule Kinase Downregulators

Jones, L. H. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.10.011 · Cited by 69 · see citing works

Evolution of Cereblon-Mediated Protein Degradation as a Therapeutic Modality

Chamberlain, P. P., D’Agostino, L. A., Ellis, J. M., Hansen, J. D., Matyskiela, M. E., McDonald, J. J., Riggs, J. R., & Hamann, L. G. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00425 · Cited by 69 · see citing works

Gambogenic acid mediated apoptosis through the mitochondrial oxidative stress and inactivation of Akt signaling pathway in human nasopharyngeal carcinoma CNE-1 cells

Yan, F., Wang, M., Chen, H., Su, J., Wang, X., Wang, F., Xia, L., & Li, Q. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.11.018 · Cited by 67 · see citing works

Dihydroartemisinin selectively inhibits PDGFRα-positive ovarian cancer growth and metastasis through inducing degradation of PDGFRα protein

Li, X., Ba, Q., Liu, Y., et al. (2017) · Cell Discovery · doi:10.1038/celldisc.2017.42 · Cited by 64 · see citing works

Specific stereochemistry of OP-1074 disrupts estrogen receptor alpha helix 12 and confers pure antiestrogenic activity

Fanning, S. W., Hodges-Gallagher, L., Myles, D. C., Sun, R., Fowler, C. E., Plant, I. N., Green, B. D., Harmon, C. L., Greene, G. L., & Kushner, P. J. (2018) · Nature Communications · doi:10.1038/s41467-018-04413-3 · Cited by 64 · see citing works

Development of Heat Shock Protein (Hsp90) Inhibitors To Combat Resistance to Tyrosine Kinase Inhibitors through Hsp90–Kinase Interactions

Wang, M., Shen, A., Zhang, C., Song, Z., Ai, J., Liu, H., Sun, L., Ding, J., Geng, M., & Zhang, A. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01106 · Cited by 62 · see citing works

Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancer

Bradbury, R. H., Acton, D. G., Broadbent, N., Brooks, A. N., Carr, G. R., Hatter, G., Hayter, B. R., Hill, K. J., Howe, N. J., Jones, R. D. O., et al. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.02.056 · Cited by 56 · see citing works

In silico, in vitro and cellular analysis with a kinome-wide inhibitor panel correlates cellular LRRK2 dephosphorylation to inhibitor activity on LRRK2

Vancraenenbroeck, R., Raeymaecker, J. D., Lobbestael, E., et al. (2014) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2014.00051 · Cited by 56 · see citing works

A Biologist's Field Guide to Multiplexed Quantitative Proteomics

Bakalarski, C. E., & Kirkpatrick, D. S. (2016) · Molecular & Cellular Proteomics · doi:10.1074/mcp.o115.056986 · Cited by 56 · see citing works

Inhibition of the checkpoint kinase Chk1 induces DNA damage and cell death in human Leukemia and Lymphoma cells

Bryant, C., Scriven, K., & Massey, A. J. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-147 · Cited by 54 · see citing works

A Fragment-Derived Clinical Candidate for Antagonism of X-Linked and Cellular Inhibitor of Apoptosis Proteins: 1-(6-[(4-Fluorophenyl)methyl]-5-(hydroxymethyl)-3,3-dimethyl-1 H ,2 H ,3 H -pyrrolo[3,2- b ]pyridin-1-yl)-2-[(2 R ,5 R )-5-methyl-2-([(3R)-3-methylmorpholin-4-yl]methyl)piperazin-1-yl]ethan-1-one (ASTX660)

Johnson, C. N., Ahn, J. S., Buck, I. M., Chiarparin, E., Day, J. E. H., Hopkins, A., Howard, S., Lewis, E. J., Martins, V., Millemaggi, A., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00900 · Cited by 53 · see citing works

Nonradioactive quantification of autophagic protein degradation with L-azidohomoalanine labeling

Wang, J., Zhang, J., Lee, Y. M., Ng, S., Shi, Y. P., Hua, Z., Lin, Q., & Shen, H. (2017) · Nature Protocols · doi:10.1038/nprot.2016.160 · Cited by 52 · see citing works

Quantitative analysis of newly synthesized proteins

Ma, Y., McClatchy, D. B., Barkallah, S., Wood, W. W., & Yates, J. R. (2018) · Nature Protocols · doi:10.1038/s41596-018-0012-y · Cited by 51 · see citing works

Phosphorylation induced cochaperone unfolding promotes kinase recruitment and client class-specific Hsp90 phosphorylation

Bachman, A. B., Keramisanou, D., Xu, W., Beebe, K. E., Moses, M. A., Kumar, M. V. V., Gray, G., Noor, R. E., van der Vaart, A., Neckers, L., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02711-w · Cited by 50 · see citing works

MYC is a critical target of FBXW7

Sato, M., Barrueco, R. R., Yu, J., Do, C., Silva, J. M., & Gautier, J. (2014) · Oncotarget · doi:10.18632/oncotarget.3203 · Cited by 49 · see citing works

Small-molecule androgen receptor downregulators as an approach to treatment of advanced prostate cancer

Bradbury, R. H., Hales, N. J., Rabow, A. A., Walker, G. E., Acton, D. G., Andrews, D. M., Ballard, P. G., Brooks, N. A. N., Colclough, N., Girdwood, A., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.06.122 · Cited by 47 · see citing works

Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ERα+ Breast Cancer

Burks, H. E., Abrams, T. J., Kirby, C. A., Baird, J., Fekete, A., Hamann, L. G., Kim, S., Lombardo, F., Loo, A. T., Lubicka, D., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01468 · Cited by 47 · see citing works

Phosphorylation of LRRK2: from kinase to substrate

Lobbestael, E., Baekelandt, V., & Taymans, J. (2012) · Biochemical Society Transactions · doi:10.1042/bst20120128 · Cited by 45 · see citing works

Identification of novel,in vivoactive Chk1 inhibitors utilizing structure guided drug design

Massey, A. J., Stokes, S. P., Browne, H. L., Foloppe, N., Fiumana, A., Scrace, S., Fallowfield, M., Bedford, S. T., Webb, P., Baker, L. M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5929 · Cited by 45 · see citing works

Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer

Nagasawa, J. Y., Govek, S. P., Kahraman, M., Lai, A. G., Bonnefous, C., Douglas, K. L., Sensintaffar, J., Lu, N., Lee, K., Aparicio, A. M., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00921 · Cited by 44 · see citing works

Tricyclic Indazoles—A Novel Class of Selective Estrogen Receptor Degrader Antagonists

Scott, J. S., Bailey, A., Buttar, D., Carbajo, R. J., Curwen, J., Davey, P. R. J., Davies, R. D. M., Degorce, S. L., Donald, C. S., Gangl, E. T., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01837 · Cited by 41 · see citing works

Insights into MAPK p38α DFG flip mechanism by accelerated molecular dynamics

Filomia, F., Rienzo, F. D., & Menziani, M. C. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.07.047 · Cited by 39 · see citing works

High-throughput flow cytometry for drug discovery: principles, applications, and case studies

Ding, M., Kaspersson, K., Murray, D., & Bardelle, C. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.09.005 · Cited by 38 · see citing works

Cell Adhesion Induced Using Surface Modification with Cell-Penetrating Peptide-Conjugated Poly(ethylene glycol)-Lipid: A New Cell Glue for 3D Cell-Based Structures

Teramura, Y., Asif, S., Ekdahl, K. N., et al. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b14584 · Cited by 36 · see citing works

Proteomics and pulse azidohomoalanine labeling of newly synthesized proteins: what are the potential applications?

Ma, Y., & Yates, J. R. (2018) · Expert Review of Proteomics · doi:10.1080/14789450.2018.1500902 · Cited by 36 · see citing works

Cellular screening assays using fluorescence microscopy

Blake, R. (2001) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(01)00092-3 · Cited by 35 · see citing works

Enhancer of zeste homologue 2 plays an important role in neuroblastoma cell survival independent of its histone methyltransferase activity

Bate-Eya, L. T., Gierman, H. J., Ebus, M. E., Köster, J., Caron, H. N., Versteeg, R., Dolman, M. E. M., & Molenaar, J. J. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.12.019 · Cited by 35 · see citing works

Adamantyl Antiestrogens with Novel Side Chains Reveal a Spectrum of Activities in Suppressing Estrogen Receptor Mediated Activities in Breast Cancer Cells

Min, J., Guillen, V. S., Sharma, A., Zhao, Y., Ziegler, Y., Gong, P., Mayne, C. G., Srinivasan, S., Kim, S. H., Carlson, K. E., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00585 · Cited by 35 · see citing works

Use of Rabbit Antibody IgG Bound onto Plain and Aminoalkylsilyl Glass Surface for the Enzyme-Linked Sandwich Immunoassay

Kato, K., Hamaguchi, Y., OKAWA, S., Ishikawa, E., Kobayashi, K., & Katunuma, N. (1977) · The Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a131678 · Cited by 34 · see citing works

Cellular and lysosomal uptake of methylamine in isolated rat hepatocytes

Solheim, A. E., & Seglen, P. O. (1983) · Biochemical Journal · doi:10.1042/bj2100929 · Cited by 33 · see citing works

High-Content Analysis in Preclinical Drug Discovery

Denner, P., Schmalowsky, J., & Prechtl, S. (2008) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/138620708783877780 · Cited by 33 · see citing works

Synthetic study of peptide aldehydes.

Itô, A., Takahashi, R., MIURA, C., et al. (1975) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.23.3106 · Cited by 32 · see citing works

Abstract PD4-14: GDC-0077 is a selective PI3Kalpha inhibitor that demonstrates robust efficacy in PIK3CA mutant breast cancer models as a single agent and in combination with standard of care therapies

Hong, R., Edgar, K. A., Song, K., Steven, S., Young, A. E., Hamilton, P., Arrazate, A., de la Cruz, C., Chan, C., Pang, J., et al. (2018) · Cancer Research · doi:10.1158/1538-7445.sabcs17-pd4-14 · Cited by 27 · see citing works

Immunodetection of Proteins by Western Blotting

Henderson, C. J., & Wolf, C. R. (2003) · Humana Press eBooks · doi:10.1385/0-89603-204-3:221 · Cited by 26 · see citing works

Identification of Novel Steroidal Androgen Receptor Degrading Agents Inspired by Galeterone 3β-Imidazole Carbamate

Purushottamachar, P., Kwegyir‐Afful, A. K., Martin, M. S., et al. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00137 · Cited by 25 · see citing works

Tyrosine Kinase Inhibitors Induce Down-Regulation of c-Kit by Targeting the ATP Pocket

d’Allard, D., Gay, J., Descarpentries, C., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060961 · Cited by 23 · see citing works

Targeted protein degradation via intramolecular bivalent glues

Hsia, O., Hinterndorfer, M., Cowan, A. D., Iso, K., Ishida, T., Sundaramoorthy, R., Nakasone, M. A., Imrichova, H., Schätz, C., Rukavina, A., et al. (2024) · Nature · doi:10.1038/s41586-024-07089-6 · Cited by 222 · see citing works

Chasing molecular glue degraders: screening approaches

Domostegui, A., Nieto-Barrado, L., Perez-Lopez, C., & Mayor-Ruiz, C. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00197g · Cited by 200 · see citing works

Reimagining Druggability Using Chemoproteomic Platforms

Spradlin, J. N., Zhang, E., & Nomura, D. K. (2021) · Accounts of Chemical Research · doi:10.1021/acs.accounts.1c00065 · Cited by 176 · see citing works

Haven't got a glue: Protein surface variation for the design of molecular glue degraders

Kozicka, Z., & Thomä, N. H. (2021) · Cell Chemical Biology · doi:10.1016/j.chembiol.2021.04.009 · Cited by 170 · see citing works

Progress and Challenges in Targeted Protein Degradation for Neurodegenerative Disease Therapy

Fang, Y., Wang, J., Zhao, M., Zheng, Q., Ren, C., Wang, Y., & Zhang, J. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00844 · Cited by 100 · see citing works

Development of PDE6D and CK1α Degraders through Chemical Derivatization of FPFT-2216

Teng, M., Lu, W., Donovan, K. A., Sun, J., Krupnick, N. M., Nowak, R. P., Li, Y.-D., Sperling, A. S., Zhang, T., Ebert, B. L., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01832 · Cited by 63 · see citing works

Prospecting for molecular glues

den Besten, W., & Lipford, J. R. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0620-z · Cited by 55 · see citing works

Improved Proteomics-Based Drug Mechanism-of-Action Studies Using 16-Plex Isobaric Mass Tags

Zinn, N., Werner, T., Doce, C., Mathieson, T., Boecker, C., Sweetman, G., Fufezan, C., & Bantscheff, M. (2021) · Journal of Proteome Research · doi:10.1021/acs.jproteome.0c00900 · Cited by 49 · see citing works

Unifying Catalysis Framework to Dissect Proteasomal Degradation Paradigms

Rodriguez-Rivera, F. P., & Levi, S. M. (2021) · ACS Central Science · doi:10.1021/acscentsci.1c00389 · Cited by 30 · see citing works

Study on the Graft Copolymerization of Carboxymethylcellulosewith Acrylamide

Guo, L. (2004) · Journal of Hebei University of Technology

Rate of copolymerization in strongly alternating systems: The evidence for the involvement of monomer complexes

Ebdon, J. R. (1987) · Makromolekulare Chemie Macromolecular Symposia · doi:10.1002/masy.19870100122 · Cited by 6 · see citing works

Monomer Transport in Emulsion Polymerization IV Gaseous Monomers

Merlin, J., & Schork, F. J. (2023) · Macromolecular Reaction Engineering · doi:10.1002/mren.202300048 · Cited by 4 · see citing works

A geometric approach for PV modules degradation

Nehme, B., M’Sirdi, N. K., & Akiki, T. (2014) · International Conference on Renewable Energies for Developing Countries (REDEC) · doi:10.1109/redec.2014.7038530 · Cited by 3 · see citing works

Free radical quaterpolymerization of acceptor- and donor-monomers

Braun, D., & Hu, F. (2003) · Polymer Bulletin · doi:10.1007/s00289-003-0124-5 · Cited by 7 · see citing works